ENTITY
Shanghai Henlius Biotech

Shanghai Henlius Biotech (2696 HK)

311
Analysis
Health CareChina
Shanghai Henlius Biotech, Inc develops and produces drugs. The Company develops and produces monoclonal antibody biosimilar drugs, bio betters, novel monoclonal antibodys, and other drugs. Shanghai Henlius Biotech throughout China.
more
bullishKorea Zinc
01 Oct 2024 07:00

(Mostly) Asia M&A, Sep 2024: GTJA/Haitong Sec, Korea Zinc/YPP, Hotel Property, Virgin Money, Raysum

For the month of Sep, 15 new deals were discussed on Smartkarma with an overall deal size of just ~US$23bn. The average premium for the new deals...

Logo
404 Views
Share
30 Sep 2024 00:35

Merger Arb Mondays (30 Sep) - Canvest, Henlius, CPMC, Xingda, Fuji Soft, Capitol, Dyna-Mac

This week, the highest gross spreads are Canvest (9.1%), GA Pack (8.6%), Henlius (8.1%), Shinko Electric (7.3%), China TCM (6.7%), Malaysia...

Logo
426 Views
Share
29 Sep 2024 16:02

China Healthcare Weekly (Sep29)- Henlius Privatization Update, NHSA Fee Control, Hansoh Is Exception

The approval process of Henlius' privatization is slow, but the deal will get up. Medical insurance fee control policies will continue. Different...

Logo
508 Views
Share
29 Sep 2024 07:00

Last Week in Event SPACE: DFI/JD.com/Yonghui, Alibaba/Sun Art, New World Development, Austal

It’s Sunday! Pour yourself a coffee, grab a comfortable seat, and sift through a brief summary of insights on various events discussed during the...

Logo
492 Views
Share
bullishFuji Soft Inc
28 Sep 2024 15:00

(Mostly) Asia-Pac M&A: Dyna Mac, Platinum Asset, Fuji Soft, JTower, Arvida, Korea Zinc, Sun Art

This insight provides a summary of gross/annualised spreads (on deals discussed on Smartkarma) across Asia-Pacific as at the last trading date, and...

Logo
519 Views
Share
x